What’s new

• Black Rose is exiting its ceramic binder business in Morbi, a market that has faced overcapacity.
• Management guided 15-20% revenue growth for FY27, citing new products and deeper market penetration.
• The polyacrylamide (PAM) solid project has moved from lab to pilot stage, a key step before commercialization.

Why it matters

The ceramic binder exit is a capital-allocation call. Morbi's overcapacity crushed margins in that segment; walking away frees resources for the specialty chemical lines where Black Rose has stronger pricing power. The PAM pilot is the next milestone in that pivot.

What we’re watching

• PAM solid project timeline from pilot to full-scale commercial launch.
• How the ceramic-binder exit impacts near-term working capital and inventory.
• Whether the 15-20% growth guidance holds up against raw-material inflation.

The full read

Black Rose Industries is exiting its ceramic binder business in Morbi, a move that signals a definitive shift away from commoditized products toward higher-margin specialty chemicals. The decision comes as management guided 15-20% revenue growth for FY27, driven by new products, deeper market penetration, and export expansion. For context, Q4 already showed momentum: revenue rose 38% and EBITDA jumped 90%, with margins expanding 130 bps to 11%. The strategic exit should free up resources for the company's priority projects, most notably the polyacrylamide (PAM) solid line, which has now reached pilot stage. The pilot is the critical gate. Passing it would turn a development-stage project into a near-term commercial opportunity. The open question is how quickly Black Rose can scale PAM and NMA to offset the revenue it will give up from ceramic binders.

Primary source: BSE · NSE